Relmada Therapeutics Inc

NASDAQ RLMD

Data sourced from

and

Download Data

Relmada Therapeutics Inc Free Cash Flow for the year ending December 31, 2023: USD -51.66 M

Relmada Therapeutics Inc Free Cash Flow is USD -51.66 M for the year ending December 31, 2023, a 50.23% change year over year. Free Cash Flow is the cash flow available to a company after deducting capital expenditures from operating cash flow, indicating its ability to generate cash for expansion, debt repayment, or dividends.

Relmada Therapeutics Inc Free Cash Flow for the year ending December 31, 2022 was USD -103.80 M, a -12.98% change year over year.
Relmada Therapeutics Inc Free Cash Flow for the year ending December 31, 2021 was USD -91.87 M, a -230.38% change year over year.
Relmada Therapeutics Inc Free Cash Flow for the year ending December 31, 2020 was USD -27.81 M, a -164.90% change year over year.
Relmada Therapeutics Inc Free Cash Flow for the year ending December 31, 2019 was USD -10.50 M, a -74.54% change year over year.

NASDAQ: RLMD

Relmada Therapeutics Inc

CEO	Dr. Sergio Traversa M.B.A., MBA, Pharm.D., PharmD
IPO Date	Oct. 9, 2014
Location	United States
Headquarters	2222 Ponce de Leon Boulevard, Coral Gables, FL, United States, 33134
Employees	20
Sector	Healthcare
Industry	Biotechnology

Description

Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system diseases (CNS) and other disorders in the United States. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a N-methyl-D-aspartate receptor antagonist which is in phase 3 clinical trial for the adjunctive or monotherapy treatment of major depressive disorder. The company is headquartered in Coral Gables, Florida.

Key trends